Medtronic Jumps on Positive EverFlex Peripheral Stent Trial Data

Shares of Medtronic plc (MDT - Analyst Report) rose 1.4% to eventually close at $77.18 yesterday following the release of the three-year study results of its DURABILITY II trial. The trial demonstrated the proven success of Medtronic’s self-expanding peripheral stent system – EverFlex – in offering sustained patency in the treatment of peripheral artery disease (PAD). The study results have been published in the recent issue of the Catheterization and Cardiovascular Intervention journal.

Help employers find you! Check out all the jobs and post your resume.